Heidelberg Pharma AG (LON: 0QW5)
London
· Delayed Price · Currency is GBP · Price in EUR 2.570
+0.020 (0.78%)
At close: Jan 15, 2025
Heidelberg Pharma AG Income Statement
Financials in millions EUR. Fiscal year is December - November.
Millions EUR. Fiscal year is Dec - Nov.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Aug '24 Aug 31, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 | Nov '20 Nov 30, 2020 | Nov '19 Nov 30, 2019 | 2018 - 2014 |
| Operating Revenue | 8.47 | 9.86 | 18.51 | 1.75 | 8.49 | 7.31 | Upgrade
|
| Other Revenue | - | - | - | 0.28 | 0.18 | 0.19 | Upgrade
|
| Revenue | 8.47 | 9.86 | 18.51 | 2.03 | 8.67 | 7.5 | Upgrade
|
| Revenue Growth (YoY) | -10.39% | -46.75% | 810.30% | -76.53% | 15.63% | 97.10% | Upgrade
|
| Cost of Revenue | 1.66 | 3.25 | 4.68 | 4.71 | 5.6 | 3.74 | Upgrade
|
| Gross Profit | 6.81 | 6.61 | 13.83 | -2.68 | 3.07 | 3.76 | Upgrade
|
| Selling, General & Admin | 7.33 | 6.22 | 5.99 | 4.48 | 3.97 | 3.43 | Upgrade
|
| Research & Development | 21.66 | 28.07 | 26.38 | 18.75 | 18.28 | 10.94 | Upgrade
|
| Other Operating Expenses | -0.38 | -0.14 | -0.24 | -0.07 | -0.11 | -0.11 | Upgrade
|
| Operating Expenses | 28.61 | 34.15 | 32.13 | 23.16 | 22.15 | 14.26 | Upgrade
|
| Operating Income | -21.8 | -27.55 | -18.29 | -25.84 | -19.09 | -10.5 | Upgrade
|
| Interest Expense | -0.24 | -0.76 | -0.84 | -0.49 | -0.01 | - | Upgrade
|
| Interest & Investment Income | 7.47 | 7.55 | 0.24 | - | - | - | Upgrade
|
| Earnings From Equity Investments | - | - | - | -0.01 | -0.07 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.46 | -0.46 | 0.96 | 0 | 0.02 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -4.68 | 0.21 | 0.06 | 0.09 | 0.14 | 0.34 | Upgrade
|
| EBT Excluding Unusual Items | -19.71 | -21.01 | -17.87 | -26.26 | -19.01 | -10.15 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.03 | 0.03 | 0.02 | - | 0.01 | 0.01 | Upgrade
|
| Asset Writedown | - | - | - | - | -0 | - | Upgrade
|
| Other Unusual Items | 0.63 | 0.63 | 0.07 | 0.12 | 0.63 | - | Upgrade
|
| Pretax Income | -19.04 | -20.35 | -17.79 | -26.14 | -18.37 | -10.14 | Upgrade
|
| Income Tax Expense | -0.28 | - | 1.92 | - | - | 0.01 | Upgrade
|
| Net Income | -18.77 | -20.35 | -19.7 | -26.14 | -18.37 | -10.15 | Upgrade
|
| Net Income to Common | -18.77 | -20.35 | -19.7 | -26.14 | -18.37 | -10.15 | Upgrade
|
| Shares Outstanding (Basic) | 46 | 47 | 37 | 33 | 30 | 28 | Upgrade
|
| Shares Outstanding (Diluted) | 46 | 47 | 37 | 33 | 30 | 28 | Upgrade
|
| Shares Change (YoY) | -1.26% | 25.14% | 14.56% | 8.72% | 5.98% | -0.00% | Upgrade
|
| EPS (Basic) | -0.41 | -0.44 | -0.53 | -0.80 | -0.61 | -0.36 | Upgrade
|
| EPS (Diluted) | -0.41 | -0.44 | -0.53 | -0.80 | -0.61 | -0.36 | Upgrade
|
| Free Cash Flow | -30.25 | -34.61 | -9.45 | -27.85 | -19.26 | -9.46 | Upgrade
|
| Free Cash Flow Per Share | -0.66 | -0.74 | -0.25 | -0.86 | -0.64 | -0.34 | Upgrade
|
| Gross Margin | 80.41% | 67.01% | 74.73% | -131.69% | 35.39% | 50.12% | Upgrade
|
| Operating Margin | -257.30% | -279.41% | -98.81% | -1270.65% | -220.21% | -140.15% | Upgrade
|
| Profit Margin | -221.51% | -206.38% | -106.42% | -1285.20% | -211.95% | -135.39% | Upgrade
|
| Free Cash Flow Margin | -357.10% | -351.07% | -51.03% | -1369.57% | -222.24% | -126.19% | Upgrade
|
| EBITDA | -21.1 | -26.84 | -17.7 | -25.2 | -18.46 | -9.97 | Upgrade
|
| EBITDA Margin | -249.01% | -272.20% | -95.63% | - | -212.99% | -133.06% | Upgrade
|
| D&A For EBITDA | 0.7 | 0.71 | 0.59 | 0.64 | 0.63 | 0.53 | Upgrade
|
| EBIT | -21.8 | -27.55 | -18.29 | -25.84 | -19.09 | -10.5 | Upgrade
|
| EBIT Margin | -257.30% | -279.41% | -98.81% | - | -220.21% | -140.15% | Upgrade
|
| Revenue as Reported | 10.52 | 16.8 | 19.86 | 2.31 | 9.58 | 7.96 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.